Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : UBX save search
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 3.33%
H: 0.0%
C: -3.23%
business year financial results
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 0.0%
H: 3.57%
C: 2.98%
publication potential
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DMETopline 16-week data expected in the fourth quarter of 2024
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 2.55%
H: 1.86%
C: -1.55%
ubx1325 first expected aspire study
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
Published: 2023-12-12 (Crawled : 13:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 2.55%
H: 1.86%
C: -1.55%
ubx1325 first aspire study
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: -1.15%
H: 4.65%
C: 0.0%
business financial
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: -5.26%
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
Published: 2023-09-27 (Crawled : 11:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 2.94%
H: 0.41%
C: -1.63%
ubx1325 macular results study
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
Published: 2023-06-21 (Crawled : 11:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 1.17%
H: 0.87%
C: -4.64%
ubx1325 macular aspire study diabetic
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Published: 2023-04-23 (Crawled : 00:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 0.43%
H: 2.59%
C: -5.6%
ubx1325 macular update program trial diabetic
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Published: 2022-10-31 (Crawled : 23:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 26.92%
H: 3.03%
C: -24.24%
ubx1325 macular program trial update diabetic
UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering
Published: 2022-08-18 (Crawled : 04:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: -33.52%
H: 8.51%
C: -5.4%
offering
UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME
Published: 2022-08-11 (Crawled : 22:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 115.27%
H: 1.09%
C: -28.42%
ubx1325 study phase 2
UNITY Biotechnology Reports Granting of New Employment Inducement Award
Published: 2022-06-29 (Crawled : 12:20) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 0.6%
H: 3.33%
C: 0.0%
UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors
Published: 2022-05-26 (Crawled : 12:20) - globenewswire.com
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: -0.01%
H: 5.33%
C: 3.72%
Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer
Published: 2022-04-14 (Crawled : 13:00) - biospace.com/
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 1.83%
H: 0.0%
C: -7.21%
EDIT | $5.355 -3.51% 1.2M
|
Health Technology
|
| O: -0.91%
H: 0.86%
C: -10.38%
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 2.0%
H: 6.86%
C: -2.94%
UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema
Published: 2022-04-12 (Crawled : 12:20) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 0.97%
H: 2.88%
C: -1.92%
ubx1325 macular diabetic enroll phase 2
UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
Published: 2022-02-14 (Crawled : 14:00) - biospace.com/
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 4.85%
H: 12.5%
C: 2.15%
ubx1325 eye eye disease technology disease phase 1 biotech iot phase 2 phase 3
UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates
Published: 2021-11-10 (Crawled : 17:00) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 16.74%
H: 33.82%
C: 16.54%
financial results results biotech technology iot
UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease
Published: 2021-11-09 (Crawled : 12:15) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: 0.0%
disease eye phase 1 eye disease biotech ubx1325
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
Published: 2021-11-03 (Crawled : 12:15) - globenewswire.com
UBX | $1.5 -0.66% 33K
|
Health Technology
|
| O: 17.49%
H: 0.09%
C: -12.6%
biotech technology iot granted grant awards
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.